Form 4: CalciMedica CEO Rachel Leheny Acquires 20,000 Shares in Open Market Purchase
SEC Form 4 Filing
CalciMedica's CEO, Rachel Leheny, recently purchased 20,000 shares of the company's common stock at a price of $3.75 per share.
Summary
- On November 1, 2024, Rachel Leheny, CEO of CalciMedica, Inc., acquired 20,000 shares of common stock.
- The purchase price was $3.75 per share.
- Following the transaction, Ms. Leheny directly owns 130,926 shares.
- She also has indirect ownership through her spouse and several Valence Investments SPVs.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase suggests confidence, but it's a single transaction and doesn't guarantee future performance.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's important to consider the overall context of the company's performance and industry trends.
Key Dates
| Date | Description |
|---|---|
| 11/01/2024 | Date of the transaction: Rachel Leheny purchased 20,000 shares of CalciMedica common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.